Anthocyanins Inhibit Nuclear Factor-B 31/05/2010
Multiple effects of anthocyanins inhibiting influenza (flu) virus infectivity 31/05/2010
Cardiovascular study on Medox and cholesterol and CETP 31/05/2010
Biolink Group AS was established in 1998 based on scientific research on flavonoids, concentrating on anthocyanins, carried out at the University of Bergen in Norway since the early eighties. Biolink’s subsidiary, Biosynth AS, has completed the seemingly impossible task of synthesizing catechomaline-structured anthocyanins.
What are anthocyanins?
Anthocyanins are small molecules, and a few of these molecules hold a catecholamine structure. The catecholamine-structured molecules concentrated in the unique Biolink nutraceutical product Medox®, posess a vast number of interesting, biological and medical properties like:
- Triggering genes, proteins and hormones
- Modulating the endocrine system (eNOS, iNOS, nNOS)
- Lowering chronic inflammation (NF-kB, +++)
- Modulating the cholesterol balance through the CETP pathway
- Modulating the immune defense system including glutathione (GSH) capacity
- Impeding growth and spread of cancer cells (Apoptosis, MMP, COX-2, NF-kB, VEGF, p38, p53, TNF-k, CETP,...)
- Lowering oxidative stress
Having realized the sensational health promoting properties of the natural catecholamine-structured anthocyanins, one will certainly appreciate that Biosynth’s synthesized Cyanidin 3-Glucoside (C3G) and Delphinidin 3-Glucoside (D3G) and more, being 100% equal to the natural ones, open a whole new giant area of application possibilities within life science. Biosynth’s goal has been to provide a synthesized version of these healthpromoting molecules in kilos and tons at a commercially acceptable cost. Fulfilling this goal opens a newmultimillion dollar business within life science.
Synthesized anthocyanins for commercial life science applications
Bioactive, synthetic, health promoting catecholamine-structured molecules are being scaled up for commercial life science applications by Biosynth AS. To verify the importance of this achievement, and to grasp the giant health promoting possibilities being made available, one has to take a short glance at Biosynth’s two associated companies, Polyphenols and MedPalett. These companies have, for more than a decade, been researching the health promoting effects of the natural catecholamine-structured anthocyanins, C3G and D3G and other polyphenols.
Polyphenols AS has supplied research organizations with pure single anthocyanin molecules and otherpolyphenols for medical and nutrition scientific research since 1998. The company’s 6-700 customers, among whom one will find both nutritional- and pharmaceutical giants, are located in more than 45 countries around in the world, and in more than 30 states in USA. The research activity cover areas like food, wine, diagnostics andpharmaceutical research within cardiovascular diseases, chronic inflammation, cholesterol, cancer, dementia, MS, the metabolic syndrome (including diabetes 2), and more.
MedPalett AS has developed a patented, highly specified, high-tech process in order to manufacture volume of pure, natural, stable, catecholamine-structured anthocyanins that are absorbed when orally consumed, and that penetrate the blood/brain barrier and the cell walls. This substance is put into capsules (80 mg), resulting in the unique and biologically active nutraceutical Medox® (on the Norwegian market since year 2000).
Biosynth AS: The world’s first synthesized anthocyanins
Fact sheet Biosynth AS, a Biolink Group company
Documentation through clinical studies
As opposed to nutritional supplements, both Medox® and the key catecholamine-structured anthocyanin molecules in the product, C3G and D3G, have been subject to free, medical, clinical studies at universities and university hospitals in Norway, EU, People’s Republic of China and in USA since the year 2000. Studies have been published in highly respected international nutritional and medical research journals like:
- ”The Journal of Nutrition”, USA-2007, chronic inflammation
- ”The American Journal of Clinical Nutrition”, USA-2007, vascular diseases, cholesterol, CETP
- ”Clinical Chemistry”, USA-2011, vascular diseases
- ”Arteriosclerosis, Thrombosis and Vascular Biology”, USA-2007, chronic inflammation
- ”The Journal of Federation of American Societies for Experimental Biology”, USA-2004, cancer
- ”The Journal of Lipid Research”, USA-2011, diabetes
- “Molecular and Cellular Biochemistry”, USA-2011, vascular diseases
The path to synthesized anthocyanins
As early as in 2001, Biosynth started the basic research in order to synthesize the catecholamine-structured anthocyanins and their metabolites. Knowing that this would be a major challenge, the scientist could lean on many years of basic research on natural counterparts of anthocyanins at the University of Bergen, Norway.
After years of extensive research, Biosynth AS, as the first in the world, succeeded in synthesizing the two most biologically active anthocyanin molecules, Cyanidin 3-Glucoside and Delphinidin 3-Glucoside, and their metabolites and thereby opening up for volume-production. Our R&D effort on synthetic anthocyanin molecules has advanced steadily, adding more anthocyanins and metabolites to the library of molecules ready for up-scaling.
As of January 1st 2011, we had synthesized a handful of anthocyanin molecules and their metabolites. The synthesizing processes and applications are continuously being patented. The filed patents have been approved in Europe and Asia and are on its way from USA and Australia.
In 2010/2011, cooperation with Solvias AG, a Swiss company: “supporting the research and development of drug substances and the optimization of manufacturing processes for pharmaceutical, biotechnology and life sciences companies worldwide” provided the final competence and access to complex, high tech, high cost, research and up-scaling manufacturing equipment.
Some possible applications for synthetic anthocyanins:
- Medicine platforms
- Immune defense stimulation
- Glutathione stimulation
- Cholesterol modulation
- Cardiovascular protection
- Cancer treatment added supplement
- Animal- and fish farming medicines
The road ahead - commercialization
Our synthetic molecules are 100 % equal to their natural counterparts. This way we know that the synthetic anthocyanins will be biologically active, non toxic and that they can more easily be adopted as low cost replacements of natural molecules.
The business potential of these patented, industrially available anthocyanins is believed to be gigantic.
Possible areas of use:
- Functional foods and beverages
- Food coloring
- Diagnostic systems
- Cosmetics and skin treatment products
- Nanocrystalline solar cells
- Eco-friendly printer toner